ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Danish drugmaker H. Lundbeck will eliminate a total of 50 positions at its research centers in Denmark and the U.S. as part of a refocusing of its R&D strategy. The company, which specializes in brain diseases, says its research will increasingly be based on the relationship between the biology of a disease and its symptoms. It adds that partnerships with universities and other companies, already important, will receive even higher priority in the future.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter